


PROFOUND MEDICAL CORP.

Pioneering a new standard of care in the
treatment of prostate cancer



Disclaimer

This presentation and oral statements made during this meeting regarding Profound and its business which may include, but are not limited to, the expectations regarding the efficacy of Profound's technology in the treatment of prostate cancer. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of each entity. The forward-looking events and circumstances discussed in this presentation may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the pharmaceutical industry, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.

Company Overview

- A Canadian medical device company focused on commercializing a new patented, minimally invasive technique for the clinical management of patients with localized prostate cancer, (**TULSA**) Transurethral **UL**traSound **A**blation technology
- Founded in 2008; commenced trading on TSX Venture June 8, 2015; symbol “PRN”
- Patents: 5 issued in the US (system, method)
 7 pending in the US
 6 pending foreign applications
- Headquarters: Toronto, 33 full-time employees

Leadership Team

Steven Plymale, CEO

- More than 20 years of experience in the medical device industry
- Led Excel-Tech (Xltek) to profitability within 12 months of assuming GM role, as well as completed four acquisitions
- Served in senior management roles at **CryoCath**, **Cedara**, **Claron** and **Bluehaven**

Rashed Dewan, Interim CFO

- 15 years + of financial management experience in the technology field
- Former Controller of **Xylem AWS Canada** and Director of Finance/Controller at **Xltek**

Ron Kurtz, VP Engineering

- 20 years + of experience in engineering management and design, primarily focused on medical device development
- Former VP of R&D at **Xltek**; over 16 years successfully developed, patented and commercialized broad portfolio of diagnostic neurology products
- Deep knowledge of product life cycle management

Goldy Singh, VP Quality and Regulatory Affairs

- 15 years of experience in Quality & Regulatory Affairs in the medical device industry for a number of companies
- Former Director of Quality and Regulatory Affairs at **Xltek**; secured 510(k) and CE Mark approvals
- Successfully launched products into the U.S., Canada and Europe

Hartmut Warnken, VP International Sales

- 13 years of experience in the medical technology industry
- Former Vice President & General Manager Europe, Middle East, Japan and Asia Pacific of **IMRIS Pte. Ltd.**, **IMRIS Germany GmbH**, **IMRIS KK Japan**
- Proven experience and success in managing entire business operations

Board of Directors

Jean-François Pariseau, Partner, BDC Venture Capital

Damian Lamb, Genesys Capital Partners Co-Founder and Managing Director

Steven Plymale, CEO, Profound Medical Corp.

William E. Curran, previously Pres. and CEO Philips Electronics North America

Arun Menawat, President and CEO, Novadaq Technologies Inc.

Jonathan Goodman, President & CEO, Knight Therapeutics

Partnership

PHILIPS

- Joint Development Agreement signed February 2015 to support Profound Medical's proprietary TULSA technology designed to treat patients with prostate cancer on Philips' Ingenia and Achieva 3T MRI systems

What if?

What if you could treat localized prostate cancer in 2 hours

Minimally invasively

With real-time image guidance


As an outpatient

With the same or even better outcomes than surgery or radiation

What would you do?


Prostate Cancer Incidence

One in 7 men will be diagnosed with prostate cancer in their lifetime



Incidence


Approximately 500,000 new cases diagnosed worldwide per year
with a US\$40 billion market



500,000 new patients/yr
850,000 procedures/yr
US\$40 billion market

Prostate Cancer Market (EU and US)

of Procedures




Total Market (US\$B): Surgery \$18.4, Radiation \$20.3, HIFU \$0.9, Cryo \$0.7

■ Surgery ■ Radiation ■ HIFU ■ Cryo


The Problem

While survival rates are high, current therapies bring undesirable complication rates



Complication Rates

Profound's technology results in fewer significant complications




*Thompson (Chair) et al for AUA Prostate Cancer Clinical Guideline Update Panel (2007) Guideline for the management of clinically localized prostate cancer: 2007 update. The Journal of Urology 177(6): 2106-31

*PMI 12-month Phase 1 Trial, GCP-10102 Table 10.

The Profound Solution

Advantages:

- Safe, fast and accurate
- Millimeter accuracy ablates cancerous tissue while sparing nearby critical structures
- Outpatient procedure with single treatment and rapid recovery time
- Minimally-invasive (transurethral) approach using thermal ablation to heat the prostate from the inside-out
- Guided by real-time MR imaging with temperature (thermometry) feedback
- Technology compatible with all leading MRI platforms



System Components

Capital Equipment




Disposables




Endorectal
Cooling Device




The Procedure




1. Patient on MRI bed



2. Patient in MRI scanner




3. Probe inserted into patient urethra



4. MR imaging of prostate in slices.


TULSA vs. HIFU

	TULSA (Profound Solution)	HIFU (Competitor Solution)
Imaging	MRI-Guided	Ultrasound-Guided
Treatment	Planar	Focused
Location	Trans-urethral	Trans-rectal
Volume	<90cc	<40cc
Duration	~40 minutes	~3 hours
Pre-Treatment	None	TURP, ADT



Proven Accuracy

Testing in prostates showed excellent agreement between MRI temperature measurements, histology and contrast-enhanced MRI



MR Thermometry

□ 0% cell kill, all tissues outside are normal

Histology

△ 100% cell kill, all tissues inside are killed


Contrast-Enhanced MRI

— Prostate
— Region of non-perfusion


Reduced Tissue Damage

Our preclinical study observed 83% of urethral tissue was preserved after treatment

Inside-out



Outside-in




Phase 1 Clinical Trial 12-month data

The Phase I trial has demonstrated that MRI-guided TULSA provides accurate treatment planning, real-time thermal dosimetry and precise control of prostate ablation to within 1.3 mm, with a well-tolerated side-effect profile.


Outcomes:

- 30 patients treated with at least 12 month follow-up
No intraoperative complications, no rectal injury or fistula
- Erectile dysfunction rate of 8% (IIEF item 2 \geq 2)
- At 12 months, only 1 patient (3%) with Grade 1 urinary incontinence (no pads)
- Functional quality-of-life outcomes back to baseline levels.

Milestones and Commercialization




Path to Commercialization




Pivotal Trial Costs

Pivotal Trial cost is estimated at \$7,000,000



Commercialization Plans


Europe, 2016



Canada, 2016




U.S., 2017



Commercial Launch in Europe

Logistics Headquarters - Netherlands
Operations Base - Germany



Capitalization

Exchange & Ticker		TSXV: PRN
Cash (@ June 30, 2015)		\$26.0MM
Debt:	FedDev	\$0.8MM
	HTX	\$1.5MM
	Knight	\$4.0MM
Common Shares (@ August 25, 2015)		
Basic, Fully Diluted		39.5MM; 42.9MM
Significant Shareholders:	BDC	24.9%
	Genesys	23.1%
	Knight	7.7%
Market Capitalization (@ \$1.50/share)		\$64.3MM

Contact



TSXV: PRN

647-476-1350

profoundmedical.com